Oncology Cardiology / Cardiovascular Respiratory / COPD / Asthma Infectious Disease Gastroenterology Diabetes / Metabolic Neurology Women's Health Rheumatology Mental Health / Psychiatry Dermatology Rare Diseases Men's Health
Clinical Trial ● Currently Recruiting NCT05765786

Diagnosing Variable Primary Aldosteronism.

Diagnosing Variable Primary Aldosteronism. — Recruiting • Cardiology / Cardiovascular • NCT05765786.

📅 08 Sep 2026 ⏱ 1 min read
Currently Recruiting
This trial is actively seeking participants in the UK. Discuss eligibility with your patient before referring.
Status
Currently Recruiting
NCT ID
NCT05765786
Sponsor
Queen Mary University of London
Start
2023-02-24
ClinicaliQ Trial Snapshot
  • Diagnosing Variable Primary Aldosteronism. — Recruiting • Cardiology / Cardiovascular • NCT05765786.
  • What is being tested: The study investigates whether patients with Primary Aldosteronism exhibit cyclical or exaggerated diurnal (daily) variations in aldosterone production, potentially identifying a distinct aldosterone secretion pattern that could aid diagnosis.
  • Patient eligibility overview: The study recruits individuals diagnosed with or suspected of having Primary Aldosteronism, though specific inclusion/exclusion criteria would be detailed in the full protocol.
Use This Page For
  • Quick orientation before opening the registry record.
  • Checking recruitment status, phase and sponsor at a glance.
  • Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying

The goal of this observational study is to see if there is a cyclical or exaggerated diurnal variation in aldosterone production in people with Primary Aldosteronism.

Eligibility Snapshot
  • : * People with clinically suspected PA but have not met criteria for diagnosis. Suspicion based on low-renin (renin activity

Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.

Full Trial Details
View this trial on the source registry
Eligibility criteria, protocol, and results when available
View Trial ↗
Share: Twitter/X LinkedIn
Related

Related Clinical Intelligence

Guidelines, Drug Science, safety briefs and education connected to this trial area.

Guideline
Semaglutide for reducing the risk of major adverse cardiovascular events in people with cardiovascular disease and overweight or obesity
Cardiology / Cardiovascular · 07 May 2026
Semaglutide is recommended for adults with established cardiovascular disease and overweight/obesity to reduce major adverse cardiovascular events – consider prescribing as part…
View guideline →
Guideline
Artificial intelligence (AI)-assisted echocardiography analysis and reporting to support the diagnosis and monitoring of heart failure: early-use assessment
Cardiology / Cardiovascular · 19 May 2026
AI-assisted echocardiography can support faster preliminary analysis and reporting of echo images in heart failure patients, potentially reducing reporting delays and improving…
View guideline →
Clinical Brief
Weight-loss jabs will be offered on NHS for people at risk of further heart attacks
Cardiology / Cardiovascular · BBC Health · 31 Mar 2026
GLP-1 receptor agonists (weight-loss jabs) will now be offered on NHS to over 1 million people in England at high cardiovascular risk,…
View brief →
Clinical Brief
Meet the teenagers calling for action on violence against women and girls
Cardiology / Cardiovascular · BBC Health · 28 Jul 2026
Teenage activists are mobilising public engagement on violence against women and girls (VAWG), highlighting widespread concern among younger generations about this health…
View brief →
Clinical Brief
Treadmills to deadlifts: Why Gen Z are swapping cardio for strength training
Cardiology / Cardiovascular · BBC Health · 24 Sep 2026
Key Takeaways for Clinical Practice Shift in exercise patterns: Younger patients are increasingly prioritising strength training over traditional steady-state cardio, reflecting broader…
View brief →
Guideline
Sotatercept for treating pulmonary arterial hypertension
Cardiology / Cardiovascular · 03 Jun 2026
Sotatercept is recommended as a treatment option for pulmonary arterial hypertension (PAH) in patients who meet NICE criteria; verify patient eligibility and…
View guideline →